InflaRx N.V. received a notice from Nasdaq stating its common shares closed below $1.00 for 30 consecutive days. The company has 180 days to regain compliance or face transfer to The Nasdaq Capital Market. The bid price rule non-compliance has no immediate effect on trading. InflaRx is a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system. Founded in 2007, InflaRx has offices in Germany and the USA. Vilobelimab, an anti-C5a monoclonal antibody, has shown promise in clinical studies, while INF904 is an orally administered C5a receptor inhibitor in development. Contacts for further information are provided in the press release.

Read more at GlobeNewswire: InflaRx Announces Receipt of Nasdaq Deficiency Notice